EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study

Gili Joseph, Ili Margalit, Yael Weiss-Ottolenghi, Carmit Rubin, Havi Murad iD, Raquel C Gardner, Noam Barda iD, Elena Ben-Shachar, Victoria Indenbaum iD, Mayan Gilboa, Sharon Alroy-Preis, Yitshak Kreiss und 2 weitere

Viruses · 2024

DOI: 10.3390/v16121955 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Viruses, 2024. Verfasst von Gili Joseph und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Sheba Pandemic Preparedness Research Institute (SPRI), Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health Israel, Israeli Ministry of Health, SMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Millions of individuals worldwide continue to experience symptoms following SARS-CoV-2 infection. This study aimed to assess the prevalence and phenotype of multi-system symptoms attributed to Long COVID—including fatigue, pain, cognitive-emotional disturbances, headache, cardiopulmonary issues, and alterations in taste and smell—that have persisted for at least two years after acute infection, which we define as “persistent Long COVID”. Additionally, the study aimed to identify clinical features and blood biomarkers associated with persistent Long COVID symptoms.

Methods

We sent a detailed long COVID symptoms questionnaire to an existing cohort of 1258 vaccinated adults (age 18–79 years) who had mild infection (e.g., non-hospitalized) SARS-CoV-2 Delta variant 2 years earlier. These individuals had comprehensive datasets, including blood samples, available for further analysis. We estimated prevalence of persistent long COVID two years post-infection using weighted adjustment (Horvitz–Thompson estimator) to overcome reporting bias. Multivariable logistic regression models were used to determine association of clinical features and blood biomarkers (pre-infection SARS-CoV-2 RBD-IgG, SARS-CoV-2 neutralizing antibodies, and pre-infection and post-infection neurofilament light) with prevalence of persistent long COVID.

Results

N = 323 participants responded to the survey, of whom N = 74 (23%) reported at least one long COVID symptom that had persisted for two years after the acute infection. Weighted prevalence of persistent long COVID symptoms was 21.5% (95% CI = 16.7–26.3%). Female gender, smoking, and severity of acute COVID-19 infection were significantly associated with persistent Long COVID. The blood biomarkers assessed were not significantly associated with persistent Long COVID.

Conclusions

Among vaccinated adults two years after mild infection with Delta variant SARS-CoV-2, persistent symptoms attributed to Long COVID are extremely common, certain subgroups are at higher risk, and further research into biological mechanisms and potential treatment targets is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansMiddle AgedFemaleMaleAdultAgedLongitudinal StudiesProspective StudiesYoung AdultBiomarkersAdolescentPost-Acute COVID-19 SyndromeAntibodies, ViralAntibodies, NeutralizingPrevalenceSurveys and Questionnaires

Stichwörter der Autor:innen

Long COVIDSARS-CoV-2 RBD-IgGpersistent long COVID symptomspredictorsserum Neurofilament Light chain (NfL)

Substanzen

BiomarkersAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • The Sheba Pandemic Preparedness Research Institute (SPRI), Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
  • Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
  • Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 6997801, Israel.
  • Data Management Unit, Gertner Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
  • Clinical Research, Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
  • Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva 8548800, Israel.

ORCID-Profile: Havi Murad, Noam Barda, Victoria Indenbaum, Gili Regev-Yochay

Förderung

  • Ministry of Health Israel
  • Israeli Ministry of Health
  • SMC

Zitieren

APA

Joseph, G., Margalit, I., Weiss-Ottolenghi, Y., Rubin, C., Murad, H., Gardner, R. C., Barda, N., Ben-Shachar, E., Indenbaum, V., Gilboa, M., Alroy-Preis, S., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2024). Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study. Viruses. https://doi.org/10.3390/v16121955

Vancouver

Joseph G, Margalit I, Weiss-Ottolenghi Y, Rubin C, Murad H, Gardner RC, et al. Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study. Viruses. 2024. doi:10.3390/v16121955

BibTeX
@article{Joseph2024,
  author = {Joseph, Gili and Margalit, Ili and Weiss-Ottolenghi, Yael and Rubin, Carmit and Murad, Havi and Gardner, Raquel C and Barda, Noam and Ben-Shachar, Elena and Indenbaum, Victoria and Gilboa, Mayan and Alroy-Preis, Sharon and Kreiss, Yitshak and Lustig, Yaniv and Regev-Yochay, Gili},
  title = {Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16121955}
}
Kostenlos starten →